1. An introduction to CAR immunotherapy2. Components and design of Chimeric Antigen Receptors (CARs)3. scFv cloning, vectors and CAR production in laboratory for preclinical application4. Production of CAR-T cells for clinical application5. Challenges and opportunities to improve CAR-TE cell therapy
Dr. Mumtaz Balkhi brings dual backgrounds in cancer biology and immunotherapeutics to a research program in translational research. With a Ph.D. in Human Biology, he applies molecular biology techniques and utilizes his knowledge of molecular and cellular immunology to develop new gene therapies to improve immunotherapies against cancer. He has more than 20 publications in highly reputable journals including Science and Cell Press Journals. His 2013 publication in Science Signaling Journal featured as Cover Story and his latest publication in Cell Press journal was recently highlighted in Cell Press Crosstalk. Dr. Balkhi hopes to establish a Chimeric Antigen Receptor (CAR) Immunotherapy program. He is trained in this field and had an opportunity to drive and lead projects related to CAR Immunotherapy.